Expertise(EN)

Effective market access and optimal product positioning require the identification of opportunities and barriers as well as the definition of individual goals and tactical plans, which we develop in close cooperation with our clients.

Based on the client's expectations and objectives, a fundamental situation analysis is necessary. Strategies that cannot be implemented according to standardized patterns require individual measures. Our extensive industry experience is the prerequisite for finding the right starting points to achieve the desired target state.

The positioning of our service and product portfolios is optimised through continuous reporting to the client and adaptation to changing conditions.

The power of the PERI Group and its experts ensures, especially in the most sensitive phases of reimbursement projects, that support is actually available when it is needed. The large number of our projects ensures that we learn early on about trends and developments that may be of relevance to our clients.

We accompany and provide support throughout the entire market access process for new drugs and indications. In the course of this process, we develop an individual strategy together with the client. On the basis of a detailed scenario plan drawn up by us consisting of base, best and worst case scenarios, which also serve for internal customer communication and discussion purposes, our customers learn which path they want to take with their product in the long term. We also provide support and advice throughout the entire pricing process.

Comprehensive support also includes the involvement of relevant stakeholders and experts at the medical and political levels. Knowledge is generated and shared with selected people from specialist circles.

We make our extensive expertise available for strategic consulting and operational implementation throughout the entire reimbursement process. All documents required for the evaluation process, i.e. pharmacological, medical-therapeutic and economic evaluation, are prepared jointly in close coordination and according to the client's ideas. Alternatively, we also take care of the submission and electronic communication with the main association during the entire procedure.

In addition to the reimbursement procedure for approved drugs, we also have broad experience in the reimbursement of products not approved as drugs, such as the award of the S or DS mark or inclusion in the reimbursement catalogue for therapeutic aids and aids.

The identification of relevant experts and scientific leaders as well as ongoing communication in one-on-one meetings or within the framework of advisory boards and round tables serve as the basis for successful market access.

Open and trusting feedback from experts on products and services enables direct access knowledge from practice. The opinions and thoughts of Scientific Leaders are the optimal resource to access the best applicable knowledge nationwide and to be able to determine decisive points of view which are most relevant for the concrete task.

Awareness is created by reporting on still too little known clinical pictures, as well as on treatment options, periods and gaps in care. Scientific Leaders will highlight specific approaches and therapeutic challenges that place the topic in the right and most important places in healthcare.

Interface management between the applied research of the pharmaceutical and medical device industry on the one hand and clinical practice on the other hand is vitally important. Industry competence, communication competence and competence in solving problems are required. On the basis of a clear conception of content and detailed literature research, meaningful publications are created which communicate important medical facts to the outside world.

Through professional medical writing in both German and English, medical priorities are presented and made public, including professional preparation of studies and statistical raw data. In order to ensure that the valuable findings of expert discussions are further dealt with and that their outcome is not lost, it is necessary to draw up new drugs/expert/consensus papers or guidelines. Texts of this kind must be agreed and coordinated with experts in order to give them the necessary credibility.

Awareness must be created above all in those healthcare sectors with a lack of health literacy or knowledge as well as important information about a disease. The aim for each person affected is to be able to make appropriate decisions independently.  Health literacy is an indispensable part of basic education and should include knowledge, motivation and action competence.

Research into current patient flows and areas with a lack of information is essential for improving the quality of life and builds the basis for improvements in care.

The stakeholder magazine "PERISKOP", the PERI Group has been offering a well-founded and up-to-date insight into the network of health, society and politics for more than 20 years. As a magazine for decision-makers, experts and journalists in the Austrian health care system, the PERISKOP published 6 times a year and reaches around 6,000 stakeholders. www.periskop.at

Decisions in health care primarily concern the patient. Despite all efforts to strengthen its position, there are still a number of barriers that prevent adequate consideration of the patient's interests. The aim of the Austrian Patient Report is to offer patients the opportunity to articulate their actually felt wishes and needs, their subjective experience, in a transparent way that is as

Independent as possible. In this way, the key players in the Austrian health system are able to align their decisions to the original interests of the patients. www.patientenbericht.at/

The market access lifecycle does not end with the reimbursement process; beyond the decision to include it in the reimbursement code, we continue to be a reliable partner. Even after a successful launch on the Austrian market, the company offering the service may still face further hurdles.

Longer-term price strategies can also be developed and pursued offensively, and various price maintenance options are conceivable for implementation. Especially towards the end of the product life cycle, the reimbursement situation can again be fundamentally optimized, for example by proactively eliminating prescription barriers.